▲ +75.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adamis Pharmaceuticals in the last 3 months. The average price target is $1.25, with a high forecast of $1.50 and a low forecast of $1.00. The average price target represents a 75.73% upside from the last price of $0.71.
The current consensus among 3 polled investment analysts is to hold stock in Adamis Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.